About: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 July 1992

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в липні 1992 (uk) artículu científicu espublizáu en xunetu de 1992 (ast) im Juli 1992 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 July 1992 (en)
publication date	wds:Q61651563-21EBF2B7-B67B-494B-A507-591879432A6D
publication date	1992-07-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q61651563-0AE77C60-B28A-48F7-899C-EF91E670CB26
language of work or name	English
rdfs:label	Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro (en) Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro (nl)
skos:prefLabel	Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro (en) Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro (nl)
name	Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro (en) Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter Euro (nl)
title	wds:Q61651563-58778D69-0821-4D2C-A1AD-12035668187E
title	Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group (en)
page(s)	wds:Q61651563-0EE86880-EF72-4109-919E-F4D0427F91E2
page(s)	100-110
instance of	wds:Q61651563-82E1B895-5D74-4810-922B-32ECB0CF98B9
instance of	scholarly article
main subject	wds:Q61651563-0D44639D-B162-474F-B290-6C6E88D6D819 wds:Q61651563-398805B3-CCA8-4069-BD96-25D36F1CF4EE wds:Q61651563-D89ED539-3800-4D2D-A005-E0F88A96261A
main subject	placebo multicenter clinical trial angioplasty
PubMed ID	wds:Q61651563-370B9D39-1D15-4A98-9B44-77BB50F1E961
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/1535568
PubMed ID	1535568
published in	wds:Q61651563-8D705D75-C8FB-462E-B968-F860C0670E3B
published in	Circulation
issue	wds:Q61651563-BDF592BB-5928-4CE7-8466-FDE3C66A8B8A
volume	wds:Q61651563-9D2F4D9E-867C-4F44-96A6-D1F45DDF7D67
issue	1
volume	86
DOI	wds:Q61651563-856AA2E1-AF13-405B-B01D-AE6060C6E30F
DOI	http://dx.doi.org/10.1161/01.CIR.86.1.100
DOI	10.1161/01.CIR.86.1.100
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q61651563
is cites work of	Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease Gene expression profile of butyrate-inhibited vascular smooth muscle cell proliferation Influence of the angiotensin converting enzyme insertion or deletion genetic variant and coronary restenosis risk: evidence based on 11,193 subjects Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors [D/D genotype of the gene for angiotensin converting enzyme as a risk factor for post-stent coronary restenosis] Neointima formation in a restenosis model is suppressed in midkine-deficient mice The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury Restenosis after coronary angioplasty Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty Cardioprotective effect of angiotensin-converting enzyme inhibitors in patients with coronary artery disease Angiotensin-converting enzyme inhibitors Targeting Gbeta gamma signaling in arterial vascular smooth muscle proliferation: a novel strategy to limit restenosis ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury Dual Determination of Angiotensin-Converting Enzyme and Angiotensin-II Type 1 Receptor Genotypes as Predictors of Restenosis After Coronary Angioplasty Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene Arterial uptake of biodegradable nanoparticles for intravascular local drug delivery: results with an acute dog model Restenosis--an open file A potent genetic risk factor for restenosis Butyrate inhibits proliferation-induced proliferating cell nuclear antigen expression (PCNA) in rat vascular smooth muscle cells Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. Overview of therapies for prevention of restenosis after coronary interventions Outcome following percutaneous coronary intervention: not, so far, in our genes Pharmacological approaches to the prevention of restenosis after coronary angioplasty Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part II). The extracellular matrix in balloon arterial injury: a novel target for restenosis prevention Endovascular stents: preliminary clinical results and future developments AT(1)-receptor blockade and the kidney: importance of non-ACE pathways in health and disease Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke Failure of protective effect of captopril and enalapril on exercise and dipyridamole-induced myocardial ischemia Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimal hyperplasia or arterial remodeling induced by balloon catheter injury in monkeys Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Quantitative coronary angiography (QCA) in interventional cardiology: clinical application of QCA measurements. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention Treating atherosclerosis: local drug delivery from laboratory studies to clinical trials The development of interventional cardiology Characterization of chymase from human vascular tissues Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease Propionyl-L-carnitine reduces intimal hyperplasia after injury in normocholesterolemic rabbit carotid artery by modulating proliferation and caspase 3-dependent apoptosis of vascular smooth muscle cells [The renin-angiotensin system in cardiovascular diseases]. Renin-angiotensin system: genes to bedside Effect of quinapril on intimal hyperplasia after coronary stenting as assessed by intravascular ultrasound Structural determinants of lumen narrowing after angioplasty in atherosclerotic nonhuman primates Validation of a new UNIX-based quantitative coronary angiographic system for the measurement of coronary artery lesions Potential Antithrombotic and Fibrinolytic Properties of the Angiotensin Converting Enzyme Inhibitors Gene therapy and vascular disease: potential applications in vascular surgery. CD143 in the development of atherosclerosis Prevention of neointima formation by mibefradil after vascular injury in rats: comparison with ACE inhibition Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study) Coronary restenosis: a review of current insights and therapies Characterisation of angiotensin II receptor mediated responses and inhibition of intimal hyperplasia in experimental vein grafts by the specific angiotensin II receptor inhibitor, L158,809 Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software